Ex Vivo Immune Responsiveness to SARS-CoV-2 Omicron BA.5.1 Following Vaccination with Unmodified mRNA-Vaccine
(1) Background: The high incidence of SARS-CoV-2 infection in vaccinated persons underscores the importance of individualized re-vaccination. PanIg antibodies that act against the S1/-receptor binding domain quantified in serum by a routine diagnostic test (ECLIA, Roche) can be used to gauge the ind...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/3/598 |
| _version_ | 1797608733584392192 |
|---|---|
| author | Anna Sabrina Kuechler Eva Heger Maike Wirtz Sandra Weinhold Markus Uhrberg Fritz Boege Karin Schulze-Bosse |
| author_facet | Anna Sabrina Kuechler Eva Heger Maike Wirtz Sandra Weinhold Markus Uhrberg Fritz Boege Karin Schulze-Bosse |
| author_sort | Anna Sabrina Kuechler |
| collection | DOAJ |
| description | (1) Background: The high incidence of SARS-CoV-2 infection in vaccinated persons underscores the importance of individualized re-vaccination. PanIg antibodies that act against the S1/-receptor binding domain quantified in serum by a routine diagnostic test (ECLIA, Roche) can be used to gauge the individual ex vivo capacity of SARS-CoV-2 neutralization. However, that test is not adapted to mutations in the S1/-receptor binding domain, having accumulated in SARS-CoV-2 variants. Therefore, it might be unsuited to determine immune-reactivity against SARS-CoV-2 BA.5.1. (2) Method: To address this concern, we re-investigated sera obtained six months after second vaccinations with un-adapted mRNA vaccine Spikevax (Moderna). We related serum levels of panIg against the S1/-receptor binding domain quantified by the un-adapted ECLIA with full virus neutralization capacity against SARS-CoV-2 B.1 or SARS-CoV-2 BA5.1. (3) Results: 92% of the sera exhibited sufficient neutralization capacity against the B.1 strain. Only 20% of the sera sufficiently inhibited the BA5.1 strain. Sera inhibiting BA5.1 could not be distinguished from non-inhibiting sera by serum levels of panIg against the S1/-receptor binding domain quantified by the un-adapted ECLIA. (4) Conclusion: Quantitative serological tests for an antibody against the S1/-receptor binding domain are unsuited as vaccination companion diagnostics, unless they are regularly adapted to mutations that have accumulated in that domain. |
| first_indexed | 2024-03-11T05:48:50Z |
| format | Article |
| id | doaj.art-fdcb30c3fa4f4584992b227486fb7d57 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T05:48:50Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-fdcb30c3fa4f4584992b227486fb7d572023-11-17T14:18:19ZengMDPI AGVaccines2076-393X2023-03-0111359810.3390/vaccines11030598Ex Vivo Immune Responsiveness to SARS-CoV-2 Omicron BA.5.1 Following Vaccination with Unmodified mRNA-VaccineAnna Sabrina Kuechler0Eva Heger1Maike Wirtz2Sandra Weinhold3Markus Uhrberg4Fritz Boege5Karin Schulze-Bosse6Central Institute for Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, 40225 Düsseldorf, GermanyInstitute for Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, GermanyInstitute for Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, GermanyInstitute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Düsseldorf, Heinrich-Heine-University, 40225 Düsseldorf, GermanyInstitute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Düsseldorf, Heinrich-Heine-University, 40225 Düsseldorf, GermanyCentral Institute for Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, 40225 Düsseldorf, GermanyCentral Institute for Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, 40225 Düsseldorf, Germany(1) Background: The high incidence of SARS-CoV-2 infection in vaccinated persons underscores the importance of individualized re-vaccination. PanIg antibodies that act against the S1/-receptor binding domain quantified in serum by a routine diagnostic test (ECLIA, Roche) can be used to gauge the individual ex vivo capacity of SARS-CoV-2 neutralization. However, that test is not adapted to mutations in the S1/-receptor binding domain, having accumulated in SARS-CoV-2 variants. Therefore, it might be unsuited to determine immune-reactivity against SARS-CoV-2 BA.5.1. (2) Method: To address this concern, we re-investigated sera obtained six months after second vaccinations with un-adapted mRNA vaccine Spikevax (Moderna). We related serum levels of panIg against the S1/-receptor binding domain quantified by the un-adapted ECLIA with full virus neutralization capacity against SARS-CoV-2 B.1 or SARS-CoV-2 BA5.1. (3) Results: 92% of the sera exhibited sufficient neutralization capacity against the B.1 strain. Only 20% of the sera sufficiently inhibited the BA5.1 strain. Sera inhibiting BA5.1 could not be distinguished from non-inhibiting sera by serum levels of panIg against the S1/-receptor binding domain quantified by the un-adapted ECLIA. (4) Conclusion: Quantitative serological tests for an antibody against the S1/-receptor binding domain are unsuited as vaccination companion diagnostics, unless they are regularly adapted to mutations that have accumulated in that domain.https://www.mdpi.com/2076-393X/11/3/598COVID 19-serologySARS-CoV-2-neutralizationSARS-CoV-2-vaccinationSARS-CoV-2-immunitycompanion-diagnosticSARS-CoV-2 BA.5.1 |
| spellingShingle | Anna Sabrina Kuechler Eva Heger Maike Wirtz Sandra Weinhold Markus Uhrberg Fritz Boege Karin Schulze-Bosse Ex Vivo Immune Responsiveness to SARS-CoV-2 Omicron BA.5.1 Following Vaccination with Unmodified mRNA-Vaccine Vaccines COVID 19-serology SARS-CoV-2-neutralization SARS-CoV-2-vaccination SARS-CoV-2-immunity companion-diagnostic SARS-CoV-2 BA.5.1 |
| title | Ex Vivo Immune Responsiveness to SARS-CoV-2 Omicron BA.5.1 Following Vaccination with Unmodified mRNA-Vaccine |
| title_full | Ex Vivo Immune Responsiveness to SARS-CoV-2 Omicron BA.5.1 Following Vaccination with Unmodified mRNA-Vaccine |
| title_fullStr | Ex Vivo Immune Responsiveness to SARS-CoV-2 Omicron BA.5.1 Following Vaccination with Unmodified mRNA-Vaccine |
| title_full_unstemmed | Ex Vivo Immune Responsiveness to SARS-CoV-2 Omicron BA.5.1 Following Vaccination with Unmodified mRNA-Vaccine |
| title_short | Ex Vivo Immune Responsiveness to SARS-CoV-2 Omicron BA.5.1 Following Vaccination with Unmodified mRNA-Vaccine |
| title_sort | ex vivo immune responsiveness to sars cov 2 omicron ba 5 1 following vaccination with unmodified mrna vaccine |
| topic | COVID 19-serology SARS-CoV-2-neutralization SARS-CoV-2-vaccination SARS-CoV-2-immunity companion-diagnostic SARS-CoV-2 BA.5.1 |
| url | https://www.mdpi.com/2076-393X/11/3/598 |
| work_keys_str_mv | AT annasabrinakuechler exvivoimmuneresponsivenesstosarscov2omicronba51followingvaccinationwithunmodifiedmrnavaccine AT evaheger exvivoimmuneresponsivenesstosarscov2omicronba51followingvaccinationwithunmodifiedmrnavaccine AT maikewirtz exvivoimmuneresponsivenesstosarscov2omicronba51followingvaccinationwithunmodifiedmrnavaccine AT sandraweinhold exvivoimmuneresponsivenesstosarscov2omicronba51followingvaccinationwithunmodifiedmrnavaccine AT markusuhrberg exvivoimmuneresponsivenesstosarscov2omicronba51followingvaccinationwithunmodifiedmrnavaccine AT fritzboege exvivoimmuneresponsivenesstosarscov2omicronba51followingvaccinationwithunmodifiedmrnavaccine AT karinschulzebosse exvivoimmuneresponsivenesstosarscov2omicronba51followingvaccinationwithunmodifiedmrnavaccine |